Organization
Nerviano Medical Sciences
5 clinical trials
Clinical trial
A Phase I Dose Escalation Study of NMS-03597812, a PERK Inhibitor, in Adult Patients With Relapsed or Refractory Multiple MyelomaStatus: Recruiting, Estimated PCD: 2024-06-01
Clinical trial
A Phase I/II Combination Study of NMS-03305293 and Temozolomide in Adult Patients With Recurrent GlioblastomaStatus: Recruiting, Estimated PCD: 2025-06-30
Clinical trial
Phase I/II Study on Safety and Efficacy of NMS-01940153E in Adult Patients With Unresectable Hepatocellular Carcinoma (HCC) Previously Treated With Systemic TherapyStatus: Active (not recruiting), Estimated PCD: 2024-01-31
Clinical trial
A Phase I Dose Escalation Study of NMS-03305293 in Adult Patients With Selected Advanced/Metastatic Solid TumorsStatus: Active (not recruiting), Estimated PCD: 2023-03-31
Clinical trial
A Phase I/II Study of NMS-03592088, a FLT3, KIT and CSF1R Inhibitor, in Patients With Relapsed or Refractory AML or CMMLStatus: Recruiting, Estimated PCD: 2025-12-28